NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Overview Fund Activity
Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

33 hedge funds and large institutions have $1.05M invested in NeuBase Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
33
Holders Change
-2
Holders Change %
-5.71%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
5
Closed
3
Calls
$4K
Puts
$14K
Net Calls
-$10K
Net Calls Change
+$12K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
$257K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
$33K
3
VF
Virtu Financial
New York
$25K
4
Citadel Advisors
Citadel Advisors
Florida
$14K
5
Morgan Stanley
Morgan Stanley
New York
$1K

Top Sellers

1
LCM
Leisure Capital Management
California
$0
2
Vanguard Group
Vanguard Group
Pennsylvania
$371K
3
GBA
Garrison Bradford & Associates
New York
$88K
4
UBS Group
UBS Group
Switzerland
$4K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
CLOS
26
Compagnie Lombard Odier SCmA
Switzerland
$1K – – –
Morgan Stanley
27
Morgan Stanley
New York
$1K +$357 +5 +56%
LCM
28
Leisure Capital Management
California
– -$14K -161 Closed
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
– -$5K -61 Closed
Simplex Trading
30
Simplex Trading
Illinois
– -$1K -12 Closed
1
2